MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
quarter
View All ->MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate-to-severe hidradenitis suppurativa, marking an important step towards potential U.S. approval and commercialization Positive Week 16 results from the Phase 3 IZAR-1 trial in psoriatic arthritis reported, with all clinical endpoints met for sonelokimab 60 mg with induction Enrollment completed in the Phase 3 IZAR-2 trial in psoriatic arthritis,
AC Immune Third Quarter 2026 Financial and Corporate Update
AC Immune Third Quarter 2026 Financial and Corporate Update Positive clinical and regulatory progress achieved across wholly-owned pipeline ACI-7104 received FDA Fast Track designation, Investigational New Drug (IND) clearance, and reported positive Part 1 week-100 results from the Phase 2 VacSYn trial in Parkinson’s disease Positive interim safety and tolerability results from the Phase 1 trial of NLRP3 inhibitor ACI-19764 in healthy volunteers Lead candidate declared in Morphomer ® small molec
newsGlobalFoundries Reports Third Quarter 2026 Financial Results
MALTA, N.Y., Nov. 04, 2026 (GLOBE NEWSWIRE) -- GLOBALFOUNDRIES Inc. (GF) (Nasdaq: GFS) today announced preliminary financial results for the third quarter ended September 30, 2026. Key Third Quarter Financial Highlights Revenue of $1.899 billion Gross margin of 30.1% and Non-IFRS gross margin (1) of 31.4% Operating margin of 12.1% and Non-IFRS operating margin (1) of 17.9% Net income (loss) of $(270) million and Non-IFRS net income (1) of $298 million Diluted earnings (loss) per share ("EPS") of
results
View All ->MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate-to-severe hidradenitis suppurativa, marking an important step towards potential U.S. approval and commercialization Positive Week 16 results from the Phase 3 IZAR-1 trial in psoriatic arthritis reported, with all clinical endpoints met for sonelokimab 60 mg with induction Enrollment completed in the Phase 3 IZAR-2 trial in psoriatic arthritis,
AC Immune Third Quarter 2026 Financial and Corporate Update
AC Immune Third Quarter 2026 Financial and Corporate Update Positive clinical and regulatory progress achieved across wholly-owned pipeline ACI-7104 received FDA Fast Track designation, Investigational New Drug (IND) clearance, and reported positive Part 1 week-100 results from the Phase 2 VacSYn trial in Parkinson’s disease Positive interim safety and tolerability results from the Phase 1 trial of NLRP3 inhibitor ACI-19764 in healthy volunteers Lead candidate declared in Morphomer ® small molec
newsGlobalFoundries Reports Third Quarter 2026 Financial Results
MALTA, N.Y., Nov. 04, 2026 (GLOBE NEWSWIRE) -- GLOBALFOUNDRIES Inc. (GF) (Nasdaq: GFS) today announced preliminary financial results for the third quarter ended September 30, 2026. Key Third Quarter Financial Highlights Revenue of $1.899 billion Gross margin of 30.1% and Non-IFRS gross margin (1) of 31.4% Operating margin of 12.1% and Non-IFRS operating margin (1) of 17.9% Net income (loss) of $(270) million and Non-IFRS net income (1) of $298 million Diluted earnings (loss) per share ("EPS") of
third
View All ->MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate-to-severe hidradenitis suppurativa, marking an important step towards potential U.S. approval and commercialization Positive Week 16 results from the Phase 3 IZAR-1 trial in psoriatic arthritis reported, with all clinical endpoints met for sonelokimab 60 mg with induction Enrollment completed in the Phase 3 IZAR-2 trial in psoriatic arthritis,
AC Immune Third Quarter 2026 Financial and Corporate Update
AC Immune Third Quarter 2026 Financial and Corporate Update Positive clinical and regulatory progress achieved across wholly-owned pipeline ACI-7104 received FDA Fast Track designation, Investigational New Drug (IND) clearance, and reported positive Part 1 week-100 results from the Phase 2 VacSYn trial in Parkinson’s disease Positive interim safety and tolerability results from the Phase 1 trial of NLRP3 inhibitor ACI-19764 in healthy volunteers Lead candidate declared in Morphomer ® small molec
newsGlobalFoundries Reports Third Quarter 2026 Financial Results
MALTA, N.Y., Nov. 04, 2026 (GLOBE NEWSWIRE) -- GLOBALFOUNDRIES Inc. (GF) (Nasdaq: GFS) today announced preliminary financial results for the third quarter ended September 30, 2026. Key Third Quarter Financial Highlights Revenue of $1.899 billion Gross margin of 30.1% and Non-IFRS gross margin (1) of 31.4% Operating margin of 12.1% and Non-IFRS operating margin (1) of 17.9% Net income (loss) of $(270) million and Non-IFRS net income (1) of $298 million Diluted earnings (loss) per share ("EPS") of
reports
View All ->MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate-to-severe hidradenitis suppurativa, marking an important step towards potential U.S. approval and commercialization Positive Week 16 results from the Phase 3 IZAR-1 trial in psoriatic arthritis reported, with all clinical endpoints met for sonelokimab 60 mg with induction Enrollment completed in the Phase 3 IZAR-2 trial in psoriatic arthritis,
GlobalFoundries Reports Third Quarter 2026 Financial Results
MALTA, N.Y., Nov. 04, 2026 (GLOBE NEWSWIRE) -- GLOBALFOUNDRIES Inc. (GF) (Nasdaq: GFS) today announced preliminary financial results for the third quarter ended September 30, 2026. Key Third Quarter Financial Highlights Revenue of $1.899 billion Gross margin of 30.1% and Non-IFRS gross margin (1) of 31.4% Operating margin of 12.1% and Non-IFRS operating margin (1) of 17.9% Net income (loss) of $(270) million and Non-IFRS net income (1) of $298 million Diluted earnings (loss) per share ("EPS") of
newsAdvantage Solutions Reports Third Quarter 2026 Results
Strong top and bottom-line results in Experiential and Retailer Services Announces restructuring actions to drive approximately $25 million in annualized near-term net savings with $5+ million in additional annualized net savings planned over time Reiterates full-year Revenues, Adjusted EBITDA and cash flow guidance ST. LOUIS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) (“Advantage,” “Advantage Solutions,” the “Company,” “we,” or “our”), a leading business solutions
announces
View All ->
Sprott Announces Third Quarter 2026 Results
TORONTO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the three and nine months ended September 30, 2026. Management commentary "Sprott’s Assets Under Management (“AUM”) were $57.3 billion as at September 30, 2026, up 3% from $55.6 billion as at June 30, 2026 and down 4% from $59.6 billion as at December 31, 2025," said Whitney George, Chief Executive Officer of Sprott. "Stronger precious metals and critical m
Option Care Health Announces Financial Results for the Third Quarter Ended September 30, 2026
BANNOCKBURN, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights (year-over-year comparisons unless otherwise noted) Net revenue of $1,493.5 million, up 4.1% GAAP net income of $57.4 million, up 10.8% GAAP diluted earning
newsDatadog Announces Third Quarter 2026 Financial Results
Third quarter revenue grew 35% year-over-year to $1.20 billion Robust growth of larger customers, with about 4,860 $100k+ ARR customers, up from about 4,060 a year ago Launched Scout 1.0, Datadog's first specialized model, now powering Bits Investigation NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Datadog, Inc. (NASDAQ:DDOG), the leading AI-powered observability and security platform, today announced financial results for its third quarter ended September 30, 2026. "Datadog delivered a strong th
Business Digest
newsSeres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)
newsWallbox Announces Third Quarter 2026 Financial Results
newsWestlake Chemical Partners LP Announces Third Quarter 2026 Results
Magazine Focus
The New Growth Playbook: Building Businesses for Sustainable Expansion
Growth is being redefined. Expanding revenue remains important, but businesses are placing greater emphasis on profitability, cash discipline, operational efficiency, customer retention and resilience. This edition explores the changing growth playbook and the foundations required for sustainable expansion. From technology and process design to capital allocation and market reach, it examines how businesses can pursue ambition without allowing complexity, costs or uncontrolled expansion to weaken the enterprise.
For years, growth was often discussed primarily in terms of size, speed and market share. The conversation is becoming more balanced. Strong businesses also need healthy economics, efficient operations and the ability to withstand uncertainty. This edition looks at growth through that wider lens and considers how organizations can expand with greater discipline, clarity and long-term purpose in practice.
The day in focus. Delivered to your inbox.
A concise daily briefing of key stories, insights and developments, selected by our editorial team.
By subscribing, you agree to our Privacy Policy. Unsubscribe at any time.